v3.21.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (3,264,882) $ (2,440,343)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense included in - General and administrative costs 580,634 314,631
Stock-based compensation expense included in - Research and development costs 670,715 434,024
(Increase) decrease in -    
Advances on research and development contract services (76,898)
Accrued interest receivable 14,367 (14,367)
Prepaid insurance (32,803) (4,250)
Other prepaid expenses and current assets 9,294 9,174
Increase (decrease) in -    
Accounts payable and accrued expenses 46,743 (51,662)
Research and development contract liabilities (78,584) 78,645
Net cash used in operating activities (2,131,414) (1,674,148)
Cash flows from financing activities:    
Proceeds from sale of common stock units in public offering, net of offering costs 4,601,816
Net cash provided by financing activities 4,601,816
Cash:    
Net increase (decrease) 2,470,402 (1,674,148)
Balance at beginning of period 2,598,864 4,273,012
Balance at end of period 5,069,266 2,598,864
Supplemental disclosures of cash flow information:    
Interest 3,674
Income taxes
Non-cash investing and financing activities:    
Accrued offering costs (paid subsequent to December 31, 2020) $ 10,467

Source